IP Library › Granted Patent US 12,551,729
Granted Patent B2
US 12,551,729 · App. 18/467,552 · Granted Feb 17, 2026

Multi-beam neuromodulation techniques

Inventors: John Frederick Graf (Ballston Lake, NY); Christopher Michael Puleo (Niskayuna, NY); Jeffrey Michael Ashe (Gloversville, NY); Victoria Eugenia Cotero (Troy, NY); David Andrew Shoudy (Niskayuna, NY)
Assignee: GE Precision Healthcare LLC
A61N7/00A61N2007/0026A61N2007/0052A61N2007/0086
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,551,729
App. No.
18/467,552
Granted
Feb 17, 2026
Kind
B2
Abstract

The subject matter of the present disclosure generally relates to techniques for neuromodulation of a tissue that include applying energy (e.g., ultrasound energy) into the tissue at multiple regions of interest, concurrently or consecutively. The neuromodulation may result in tissue displacement, which may be observed through changes in one or more molecules of interest.

Claims (34)

1 . A method comprising:

distributing an ultrasound energy dose between a plurality of regions of interest, wherein the ultrasound energy dose is distributed between at least two separate and distinct ultrasound beams, wherein a first beam targets a first organ and a second beam targets a second organ that is different than the first organ, wherein the first organ and the second organ each receive a respective fraction of a total ultrasound energy dose, wherein energy applied to the first organ is limited below a first threshold and energy applied to the second organ is limited below a second threshold, and wherein a cumulative applied ultrasound energy to the plurality of regions of interest is equal to the total ultrasound energy dose;

assessing an effectiveness of the ultrasound energy dose; and

modifying instructions to apply a subsequent ultrasound energy dose of a neuromodulation treatment based on the assessing, wherein modifying the instructions comprises changing a relative distribution of ultrasound energy between the plurality of regions of interest of the subsequent ultrasound energy dose such that the relative distribution is changed to increase a fraction of the subsequent ultrasound energy dose applied to an individual region of interest in the first organ based on a change in concentration of one or more molecules of interest, and wherein a corresponding fraction of the total ultrasound energy dose applied to a different region of interest in the second organ is correspondingly decreased.

2 . The method of claim 1 , wherein modifying the instructions comprises selecting a different plurality of regions of interest between which fractions of the subsequent ultrasound energy dose are distributed.

3 . The method of claim 1 , wherein the first organ is a liver and the second organ is a gastrointestinal tract.

4 . The method of claim 1 , wherein the first organ is a liver or a spleen and the second organ is a gastrointestinal tract or a pancreas.

5 . The method of claim 1 , wherein the one or more molecules of interest comprises glucose.

6 . The method of claim 1 , wherein applying the ultrasound energy dose to the first organ and the second organ causes a decrease in circulating glucose concentration.

7 . The method of claim 1 , wherein the ultrasound energy dose is applied weekly.

8 . The method of claim 1 , wherein the ultrasound energy dose is applied in series to the plurality of regions of interest.

9 . The method of claim 1 , wherein the ultrasound energy dose is applied concurrently to the plurality of regions of interest.

10 . A method comprising:

receiving image data of a tissue of a subject;

dividing the image data of the tissue into a plurality of segments;

selecting a plurality of regions of interest in the tissue associated with respective segments of the plurality of segments;

controlling an ultrasound transducer to apply an ultrasound energy dose distributed between the plurality of regions of interest, wherein the ultrasound energy dose is distributed between at least two separate and distinct ultrasound beams, wherein a first beam targets a first organ and a second beam targets a second organ that is different from the first organ, wherein the first organ and the second organ each receive a respective fraction of a total ultrasound energy dose, wherein energy applied to the first organ is limited below a first threshold and energy applied to the second organ is limited below a second threshold, wherein a cumulative applied ultrasound energy dose to the plurality of regions of interest is equal to the total ultrasound energy dose, and wherein the first organ and the second organ comprise at least one axon terminal of a neuron, the axon terminal forming a synapse with a non-neuronal cell;

assessing an effectiveness of the ultrasound energy dose; and

modifying instructions to apply a subsequent ultrasound energy dose of a neuromodulation treatment based on the assessing, wherein modifying the instructions comprises changing a relative distribution of ultrasound energy between the plurality of regions of interest of the subsequent ultrasound energy dose such that the relative distribution is changed to increase a fraction of the subsequent ultrasound energy dose applied to an individual region of interest in the first organ based on a change in concentration of one or more molecules of interest, and wherein a corresponding fraction of the total ultrasound energy dose applied to a different region of interest in the second organ is correspondingly decreased.

11 . The method of claim 10 , comprising selecting a different plurality of segments and controlling the ultrasound transducer to apply a subsequent ultrasound energy dose distributed between the different plurality of segments.

12 . The method of claim 10 , wherein each segment of the plurality of segments is a same volume relative to one another.

13 . The method of claim 10 , wherein the first organ is a liver and the second organ is a gastrointestinal tract.

14 . The method of claim 10 , wherein the first organ is a liver or a spleen and the second organ is a gastrointestinal tract or a pancreas.

15 . The method of claim 10 , wherein applying the ultrasound energy dose to the first organ and the second organ causes a decrease in circulating glucose concentration.

16 . The method of claim 10 , wherein the ultrasound energy is distributed between the first organ and the second organ at a ratio of 1:1 to 1:10.

17 . The method of claim 10 , wherein the ultrasound energy dose comprises a temporal average intensity of less than 500 mW/cm 2 .

18 . A system, comprising:

an ultrasound energy application device; and

a controller configured to:

distribute an ultrasound energy dose between a plurality of regions of interest, wherein the ultrasound energy dose is distributed between at least two separate and distinct ultrasound beams, wherein a first beam targets a first organ and a second beam targets a second organ that is different than the first organ, wherein the first organ and the second organ each receive a respective fraction of a total ultrasound energy dose, wherein energy applied to the first organ is limited below a first threshold and energy applied to the second organ is limited below a second threshold, and wherein a cumulative applied ultrasound energy to the plurality of regions of interest is equal to the total ultrasound energy dose;

assess an effectiveness of the ultrasound energy dose; and

modify instructions to apply a subsequent ultrasound energy dose of a neuromodulation treatment based on the assessing, wherein modifying the instructions comprises changing a relative distribution of ultrasound energy between the plurality of regions of interest of the subsequent ultrasound energy dose such that the relative distribution is changed to increase a fraction of the subsequent ultrasound energy dose applied to an individual region of interest in the first organ based on a change in concentration of one or more molecules of interest, and wherein a corresponding fraction of the total ultrasound energy dose applied to a different region of interest in the second organ is correspondingly decreased.

19 . The method of claim 18 , wherein the first organ is a liver and the second organ is a gastrointestinal tract.

20 . The method of claim 18 , wherein the first organ is a liver or a spleen and the second organ is a gastrointestinal tract or a pancreas.

Continuity (2)
Division 16709717 · Dec 10, 2019
Related Publication 20240001159A1 · Jan 4, 2024
References Cited (41)
US 7769442B2 · Shafer · 2010 [cited by applicant]
US 9011336B2 · Slayton et al. · 2015 [cited by applicant]
US 10070911B2 · Azamian et al. · 2018 [cited by applicant]
US 10143850B2 · Cowan et al. · 2018 [cited by applicant]
US 20080033297A1 · Sliwa · 2008 [cited by applicant]
US 20090112133A1 · Deisseroth et al. · 2009 [cited by applicant]
US 20090290796A1 · Shi · 2009 [cited by examiner]
US 20100022921A1 · Seip · 2010 [cited by applicant]
US 20100030076A1 · Vortman · 2010 [cited by examiner]
US 20100081893A1 · Jarvik et al. · 2010 [cited by applicant]
US 20100234728A1 · Foley et al. · 2010 [cited by applicant]
US 20110172528A1 · Gertner · 2011 [cited by applicant]
US 20110206593A1 · Fahs, II · 2011 [cited by examiner]
US 20120197163A1 · Mishelevich · 2012 [cited by applicant]
US 20120296197A1 · Vahala et al. · 2012 [cited by applicant]
US 20130144165A1 · Ebbini · 2013 [cited by applicant]
US 20130144194A1 · Ahn · 2013 [cited by examiner]
US 20130211293A1 · Auboiroux et al. · 2013 [cited by applicant]
US 20140058292A1 · Alford · 2014 [cited by applicant]
US 20150051475A1 · Leussler et al. · 2015 [cited by applicant]
US 20150141874A1 · Wilson · 2015 [cited by applicant]
US 20150290476A1 · Krocak et al. · 2015 [cited by applicant]
US 20160199668A1 · Bharat · 2016 [cited by examiner]
US 20170281982A1 · Zhu · 2017 [cited by applicant]
US 20180082427A1 · Munukutla · 2018 [cited by examiner]
US 20180207044A1 · Sabet et al. · 2018 [cited by applicant]
US 20190076674A1 · Ergün et al. · 2019 [cited by applicant]
US 20190247066A1 · Rafter · 2019 [cited by applicant]
US 20190329075A1 · Sutton · 2019 [cited by applicant]
US 20190350557A1 · Shi · 2019 [cited by examiner]
US 20200302825A1 · Sachs et al. · 2020 [cited by applicant]
WO 2018081826A1 · 2018 [cited by applicant]
WO 2018185767A1 · 2018 [cited by applicant]
Cotero et al., “Noninvasive Sub-Organ Ultrasound Stimulation for Targeted Neuromodulation”, Nature Communications, vol. 952, pp. 01-12, Mar. 12, 2019. [cited by applicant]
Mahadevan, Vishy; “Anatomy of the Pancreas and Spleen”, Surgery (Oxford), vol. 37, Issue 6, pp. 297-301, Jun. 2019. [cited by applicant]
Martins et al., “Insulin Inhibits LPS-Induced Signaling Pathways in Alveolar Macrophages”, Cellular Physiology and Biochemistry, vol. 21, Issue: 4, pp. 297-304, Apr. 23, 2008. [cited by applicant]
Rahier et al., “Cellular Composition of the Human Diabetic Pancreas”, Diabetologia, vol. 24, Issue: 05, pp. 366-371, May 1983. [cited by applicant]
Tessaro et al., “Insulin Influences LPS-Induced TNF-A and IL-6 Release through Distinct Pathways in Mouse Macrophages from Different Compartments”, Cellular Physiology and Biochemistry, vol. 42, Issue: 05, 2093-2104, Au… [cited by applicant]
Vikram et al., “Pancreas: Peritoneal Reflections, Ligamentous Connections, and Pathways of Disease Spread”, Radiographics : a review publication of the Radiological Society of North America, vol. 29, Issue: 02, Jan. 23,… [cited by applicant]
PCT/US2020/061327; International Search Report/Written Opinion; mailed Mar. 12, 2021; pp. 1-9. [cited by applicant]
EP application 20898291.8 filed Jun. 22, 2022—extended Search Report issued Nov. 22, 2023; 9 pages. [cited by applicant]